US 11027001
Therapeutic cancer vaccines derived from a novel dendritic cell line
granted A61KA61K2039/80A61K2239/48
Quick answer
US patent 11027001 (Therapeutic cancer vaccines derived from a novel dendritic cell line) held by DCPRIME B.V. expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- DCPRIME B.V.
- Grant date
- Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/80, A61K2239/48, A61K40/19, A61K40/24